发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Risk stratification and early intervention in smoldering multiple myeloma. 阴燃型多发性骨髓瘤的风险分层及早期干预。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-24 DOI: 10.1080/10428194.2025.2576562
Manraj Singh Sra, Shaji Kumar
{"title":"Risk stratification and early intervention in smoldering multiple myeloma.","authors":"Manraj Singh Sra, Shaji Kumar","doi":"10.1080/10428194.2025.2576562","DOIUrl":"https://doi.org/10.1080/10428194.2025.2576562","url":null,"abstract":"<p><p>Smoldering multiple myeloma (SMM) is a biologically diverse precursor to multiple myeloma (MM), characterized by varying risks of progression. Several validated risk stratification models help identify patients at the highest risk, who may benefit from early treatment at the precursor stage. Current guidelines recommend treatment with lenalidomide, with or without dexamethasone, or participation in clinical trials for patients with high-risk SMM. Recent data also support using daratumumab monotherapy, which has been shown to significantly delay progression to MM. However, uncertainties remain about the long-term benefits of early intervention, especially regarding its effects on overall survival, quality of life, and the risk-benefit ratio in this asymptomatic group. This review discusses current risk stratification models for SMM, summarizes evidence from key clinical trials on prevention strategies, and highlights the evolving landscape of ongoing research.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond "favorable": early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AML. 超越“有利”：儿童RUNX1::RUNX1T1 AML的早期分子反应和结果
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-24 DOI: 10.1080/10428194.2025.2576559
Molly Gilligan, Alexandra Gomez-Arteaga
{"title":"Beyond \"favorable\": early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AML.","authors":"Molly Gilligan, Alexandra Gomez-Arteaga","doi":"10.1080/10428194.2025.2576559","DOIUrl":"https://doi.org/10.1080/10428194.2025.2576559","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia. Cladribine和venetoclax联合alemtuzumab治疗复发/难治性t细胞前淋巴细胞白血病。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-22 DOI: 10.1080/10428194.2025.2566318
Naszrin Arani, Caitlin R Rausch, Alexis Geppner, Gautam Borthakur, Nitin Jain, Alessandra Ferrajoli, Elias Jabbour, Deepa Sampath, Chitra Hosing, Francisco Vega, Hagop M Kantarjian, Tapan M Kadia
{"title":"Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.","authors":"Naszrin Arani, Caitlin R Rausch, Alexis Geppner, Gautam Borthakur, Nitin Jain, Alessandra Ferrajoli, Elias Jabbour, Deepa Sampath, Chitra Hosing, Francisco Vega, Hagop M Kantarjian, Tapan M Kadia","doi":"10.1080/10428194.2025.2566318","DOIUrl":"https://doi.org/10.1080/10428194.2025.2566318","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145346202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endothelial activation and stress index (EASIX) to predict engraftment syndrome after autologous hematopoietic cell transplantation in patients with multiple myeloma. A single center experience. 内皮活化和应激指数（EASIX）预测多发性骨髓瘤患者自体造血细胞移植后的植入综合征。单中心体验。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-17 DOI: 10.1080/10428194.2025.2556179
Carles Tolosa-Ridao, Joan Cid, Luis-Gerardo Rodríguez-Lobato, Paola Charry, José Miguel Mateos, Ana Belén Moreno-Castaño, Julia Martinez-Sanchez, Cristina Gallego, Noemí Llobet, María Suárez-Lledó, Alexandra Martínez-Roca, Beatriz Merchán Muñoz, Enric Carreras, Joan Bladé, María Teresa Cibeira, Carlos Fernández de Larrea, Laura Rosiñol, Carmen Martínez, Maribel Díaz-Ricart, Miquel Lozano, Montserrat Rovira, Francesc Fernández-Avilés, María Queralt Salas
{"title":"Endothelial activation and stress index (EASIX) to predict engraftment syndrome after autologous hematopoietic cell transplantation in patients with multiple myeloma. A single center experience.","authors":"Carles Tolosa-Ridao, Joan Cid, Luis-Gerardo Rodríguez-Lobato, Paola Charry, José Miguel Mateos, Ana Belén Moreno-Castaño, Julia Martinez-Sanchez, Cristina Gallego, Noemí Llobet, María Suárez-Lledó, Alexandra Martínez-Roca, Beatriz Merchán Muñoz, Enric Carreras, Joan Bladé, María Teresa Cibeira, Carlos Fernández de Larrea, Laura Rosiñol, Carmen Martínez, Maribel Díaz-Ricart, Miquel Lozano, Montserrat Rovira, Francesc Fernández-Avilés, María Queralt Salas","doi":"10.1080/10428194.2025.2556179","DOIUrl":"https://doi.org/10.1080/10428194.2025.2556179","url":null,"abstract":"<p><p>This study examines engraftment syndrome (ES) and the predictive role of the Endothelial Activation and Stress Index (EASIX) in multiple myeloma (MM) patients undergoing autologous hematopoietic cell transplantation (auto-HCT). We analyzed 187 patients who received at-home auto-HCT (2015-2022), assessing EASIX at pre-apheresis, post-apheresis, and hospital admission. ES occurred in 16.6% despite corticosteroid prophylaxis and G-CSF avoidance, resolving completely with treatment; only one patient required hospitalization. An EASIX cutoff of ≥0.9 may help identify high-risk patients. Higher post-apheresis EASIX values (HR 1.19, <i>p</i> = 0.03) and any grade of mucositis (HR 1.82, <i>p</i> = 0.04) were significantly associated with ES. These findings support EASIX as a valuable tool for risk stratification and personalized interventions, improving ES management. Its incorporation into clinical workflows may optimize outcomes, especially in at-home settings where rapid response is crucial to prevent readmission.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric-inspired regimen abrogates the poor prognosis of adult early T-cell precursor acute lymphoblastic leukemia. 儿科启发方案废除成人早期t细胞前体急性淋巴细胞白血病预后不良。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-16 DOI: 10.1080/10428194.2025.2558921
Jieping Lin, Chengming He, Zihong Cai, Junjie Chen, Jia Li, Changxin Yin, Huan Li, Chenhao Ding, Zhen Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou
{"title":"Pediatric-inspired regimen abrogates the poor prognosis of adult early T-cell precursor acute lymphoblastic leukemia.","authors":"Jieping Lin, Chengming He, Zihong Cai, Junjie Chen, Jia Li, Changxin Yin, Huan Li, Chenhao Ding, Zhen Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou","doi":"10.1080/10428194.2025.2558921","DOIUrl":"https://doi.org/10.1080/10428194.2025.2558921","url":null,"abstract":"<p><p>Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is recognized as a high-risk subtype of T-cell acute lymphoblastic leukemia (T-ALL). While intensified chemotherapy has demonstrated potential benefits, there is a lack of comparative studies evaluating the effectiveness of adult versus pediatric treatment regimens for adult ETP-ALL. We compared the ETP-ALL patients (<i>n</i> = 65) treated with the pediatric-inspired regimen to the historical cohort treated with the adult regimen (<i>n</i> = 44). The results showed that the pediatric-inspired regimen significantly improved the complete remission rate (91% vs. 75%, <i>p</i> = .026). The five-year overall survival was markedly higher in the pediatric-inspired regimen cohort at 66.5% compared to 26.0% in the adult regimen cohort (<i>p</i> < .001). Event-free survival also improved significantly (63.4% vs. 18.5%, <i>p</i> < .001), with lower relapse rates (12.3% vs. 60.7%, <i>p</i> < .001). Multivariate analysis confirmed that ETP-ALL is not inferior to Non-ETP-ALL, suggesting that ETP-ALL should no longer be regarded as a high-risk factor in adult T-ALL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First case report of talquetamab use in AL amyloidosis. talquetamab治疗AL淀粉样变性的首例报道。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-16 DOI: 10.1080/10428194.2025.2556175
Noa Gross Even-Zohar, Shlomzion Aumann, Adir Shaulov, Arnon Haran, Boaz Nachmias, Eyal Lebel, Roni Lehmann-Werman, Moshe E Gatt
{"title":"First case report of talquetamab use in AL amyloidosis.","authors":"Noa Gross Even-Zohar, Shlomzion Aumann, Adir Shaulov, Arnon Haran, Boaz Nachmias, Eyal Lebel, Roni Lehmann-Werman, Moshe E Gatt","doi":"10.1080/10428194.2025.2556175","DOIUrl":"https://doi.org/10.1080/10428194.2025.2556175","url":null,"abstract":"<p><p>AL amyloidosis (AL) is a rare plasma cell disorder with limited treatment options in the relapsed/refractory (R/R) setting. Talquetamab, a bispecific T-cell engager targeting GPRC5D, has demonstrated efficacy in multiple myeloma, but its use in AL has not been reported. We describe the first case of talquetamab treatment in a heavily pretreated patient with AL amyloidosis and cardiac involvement. The patient tolerated treatment well, with no cardiac toxicity, and achieved a stringent complete response with cardiac and hematologic improvement. Adverse events included dysgeusia, weight loss, and mild cytopenias, which were manageable. This case highlights the potential role of talquetamab in R/R AL, demonstrating both efficacy and safety. Further studies are needed to evaluate its broader applicability in this fragile patient population.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-6"},"PeriodicalIF":2.2,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypereosinophilia after CAR T-cell therapy. CAR - t细胞治疗后嗜酸性粒细胞增多。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-16 DOI: 10.1080/10428194.2025.2565466
Bérenger Poirier, Roch Houot, Samuel Vic, Mickael Roussel, Catherine Henry, Cédric Pastoret, Ondine Messéant
{"title":"Hypereosinophilia after CAR T-cell therapy.","authors":"Bérenger Poirier, Roch Houot, Samuel Vic, Mickael Roussel, Catherine Henry, Cédric Pastoret, Ondine Messéant","doi":"10.1080/10428194.2025.2565466","DOIUrl":"https://doi.org/10.1080/10428194.2025.2565466","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Next-generation sequencing of TCR clonality discriminates tumor-stage mycosis fungoides from coexisting CD30+ lymphoproliferative disorders. 下一代TCR克隆性测序可区分肿瘤期蕈样真菌病和共存的CD30+淋巴增生性疾病。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-16 DOI: 10.1080/10428194.2025.2568743
Juan Torre-Castro, Rebeca Manso, Miriam Morales Gallego, Socorro María Rodríguez Pinilla
{"title":"Next-generation sequencing of TCR clonality discriminates tumor-stage mycosis fungoides from coexisting CD30+ lymphoproliferative disorders.","authors":"Juan Torre-Castro, Rebeca Manso, Miriam Morales Gallego, Socorro María Rodríguez Pinilla","doi":"10.1080/10428194.2025.2568743","DOIUrl":"https://doi.org/10.1080/10428194.2025.2568743","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145308453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MiR-22-3p regulates the SIRT1/P53 signaling pathway, thereby influencing ferroptosis in diffuse large B-cell lymphoma cells. MiR-22-3p调节SIRT1/P53信号通路，从而影响弥漫性大b细胞淋巴瘤细胞的铁下垂。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-15 DOI: 10.1080/10428194.2025.2568186
Xin Lu, Liyun Zhao, Suli Guo, Nafei Chen, Yehua Zhang, Ran Chen, Jiang Licai, Zongjiu Jiao
{"title":"MiR-22-3p regulates the SIRT1/P53 signaling pathway, thereby influencing ferroptosis in diffuse large B-cell lymphoma cells.","authors":"Xin Lu, Liyun Zhao, Suli Guo, Nafei Chen, Yehua Zhang, Ran Chen, Jiang Licai, Zongjiu Jiao","doi":"10.1080/10428194.2025.2568186","DOIUrl":"https://doi.org/10.1080/10428194.2025.2568186","url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with high mortality. Ferroptosis, an iron-dependent form of programmed cell death, has potential in cancer therapy. This study investigates the role of miR-22-3p in regulating ferroptosis in DLBCL through the SIRT1/P53 pathway. Bioinformatics analysis identified key microRNAs and target genes associated with ferroptosis. Dual-luciferase assays confirmed the interaction between miR-22-3p and its target genes, while qPCR and Western blot demonstrated its regulatory effects on the SIRT1/P53 axis. Immuno-precipitation revealed the interaction between SIRT1 and P53. MiR-22-3p expression was found to be downregulated in DLBCL patients. MiR-22-3p mimic promoted apoptosis and inhibited proliferation and invasion of DLBCL cells. Knockdown of SIRT1 disrupted mitochondrial morphology, and miR-22-3p was shown to trigger ferroptosis via the SIRT1/P53 pathway.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145292702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic analysis of cell-free DNA in follicular lymphoma in comparison with tissue-derived DNA. 滤泡性淋巴瘤游离DNA与组织源性DNA的遗传分析。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-10-15 DOI: 10.1080/10428194.2025.2556961
Yoshikazu Hori, Hiroki Hosoi, Mitsuo Osuga, Ryuta Iwamoto, Fumiyo Maekawa, Tadashi Okamura, Shogo Murata, Toshiki Mushino, Motomi Osato, Hitoshi Ohno, Nobuyuki Yamamoto, Shin-Ichi Murata, Yasuhiro Koh, Sonoki Takashi
{"title":"Genetic analysis of cell-free DNA in follicular lymphoma in comparison with tissue-derived DNA.","authors":"Yoshikazu Hori, Hiroki Hosoi, Mitsuo Osuga, Ryuta Iwamoto, Fumiyo Maekawa, Tadashi Okamura, Shogo Murata, Toshiki Mushino, Motomi Osato, Hitoshi Ohno, Nobuyuki Yamamoto, Shin-Ichi Murata, Yasuhiro Koh, Sonoki Takashi","doi":"10.1080/10428194.2025.2556961","DOIUrl":"https://doi.org/10.1080/10428194.2025.2556961","url":null,"abstract":"<p><p>Early disease progression, including histological transformation, can occur in follicular lymphoma, but tumor heterogeneity makes comparison difficult. We analyzed cell-free DNA from 30 patients with follicular lymphoma to assess cell-free DNA concentration and gene mutations. Mutational profiles were also examined in 16 cases using DNA from formalin-fixed, paraffin-embedded tissue samples. Cell-free DNA concentrations were higher in cases with histological transformation. Both the number of mutations per patient and the number of mutated genes were greater in cell-free DNA than in formalin-fixed, paraffin-embedded tissue-derived DNA. Notably, <i>TP53</i> mutations were more frequently detected in cell-free DNA. <i>CIITA</i> mutations were more commonly observed in cases with a low frequency of somatic hypermutation in <i>VH</i> genes. Cell-free DNA analysis in follicular lymphoma may become a complementary approach, overcoming the limitations of assessing disease status from single biopsy sites. Further studies will examine the usefulness of cell-free DNA in predicting disease progression in follicular lymphoma.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145292701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信